[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Entrada Therapeutics director Mary Thistle received a stock option grant covering 19,000 shares of common stock. The option has an exercise price of $5.97 per share and expires on June 10, 2036. According to the terms, the award vests on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders. This is a compensation-related grant rather than an open-market trade.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Thistle Mary
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 19,000 options
Exercise price: $5.97 per share
Expiration date: June 10, 2036
+2 more
5 metrics
Option grant size
19,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$5.97 per share
Conversion or exercise price of stock option
Expiration date
June 10, 2036
Option expiration for director grant
Shares underlying options
19,000 shares
Underlying Entrada Therapeutics common stock
Vesting condition
Earlier of 1-year from June 10, 2026 or next annual meeting
Time-based vesting schedule from footnote
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.9700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest and become exercisable financial
"The shares subject to this option shall vest and become exercisable on the earlier of"
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders"
FAQ
What did Entrada Therapeutics (TRDA) director Mary Thistle report in this Form 4?
Mary Thistle reported receiving a stock option grant for 19,000 shares of Entrada Therapeutics common stock. The award is a compensation-related option, not an open-market transaction, and was reported as an acquisition under transaction code A on the Form 4.
How and when do Mary Thistle’s Entrada Therapeutics (TRDA) stock options vest?
The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada Therapeutics’ next annual meeting of stockholders. This time-based vesting ties the director’s compensation to continued service over the coming year.
How many Entrada Therapeutics (TRDA) options does Mary Thistle hold after this grant?
After this reported transaction, Mary Thistle holds 19,000 stock options directly as reflected in the Form 4. These options, if vested and exercised at $5.97 per share, would convert into an equal number of Entrada Therapeutics common shares.